🔬🩸 Hematology Updates: CNS Lymphoma Responses, BCL2 Trials, and 5-Year BTK Efficacy
From CNS-targeted therapies and real-world CAR-T validation to long-term data in high-risk CLL—this week’s hematology roundup covers the most pivotal clinical advances shaping the blood cancer landscape.
💡 Key Highlights This Week:
✅ Tirabrutinib achieves 67% response and 44% complete response in primary CNS lymphoma
🧬 InnoCare begins BCL2 inhibitor trial (mesutoclax + azacitidine) in myelodysplastic syndromes following NMPA approval
🧪 Merck’s zilovertamab vedotin shows 56.3% ORR and 50% CR in relapsed/refractory DLBCL with manageable safety
🏥 Real-world data confirms Yescarta is safe and effective for outpatient large B-cell lymphoma treatment
📈 Zanubrutinib delivers 97.3% ORR and 72.2% 5-year PFS in high-risk CLL/SLL with 17p deletions
🚀 Estrella doses second cohort in STARLIGHT-1 trial of CD19-redirected ARTEMIS T-cell therapy targeting CNS lymphoma and HIV+ patients
🔬 Iksuda initiates first-in-human Phase 1 trial of CD19-targeted ADC IKS03 across five countries
🧪 Auron launches clinical trial of oral KAT2A/B degrader AUTX-703 in relapsed/refractory AML and MDS with preclinical survival benefit
🎯 Whether you’re following BTK inhibitors, antibody-drug conjugates, or first-in-class epigenetic targets—this update delivers the clinical intelligence you need to stay informed in hematological disorders
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on blood cancers, cell therapies, and rare hematologic breakthroughs.
#Hematology #CLL #DLBCL #MDS #CNSLymphoma #CAR_T #BTKInhibitor #Zanubrutinib #ADC #BCL2 #BloodCancerResearch #BiotechNews #LucidQuest #HealthcareUpdates #AML #Epigenetics #TCellTherapy